BDTX Stock Price Chart
BDTX Price
Black Diamond Therapeutics Inc
$1.7
-8.6%
$-0.16
At close: Jun 25, 16:00:00 GMT-4
$1.74
2.35%
$0.04
Post-market: Jun 25, 19:43:43 GMT-4
Back
Black Diamond Therapeutics Inc (BDTX) Price
Key Stats
Prev.Close
$1.86
Open
$1.86
Day's Range
$1.69 - $1.89
52 week range
$1.74 - $4.94
Volume
1.9M
Avg.Volume
1.0M
Dividend yield
--
EPS (TTM)
-0.76
Market Cap
$99.7M
What is BDTX?
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 21 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The firm is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. The company is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
